Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Core Insights - Akebia Therapeutics, Inc. will present clinical data on Vadadustat at the 62nd European Renal Association Congress from June 4-7, 2025, in Vienna, both virtually and live [1] Company Overview - Akebia Therapeutics is a biopharmaceutical company founded in 2007, headquartered in Cambridge, Massachusetts, focused on improving the lives of individuals affected by kidney disease [2] - The company is fully integrated and aims to address the needs of patients with chronic kidney disease (CKD) [2] Presentation Highlights - Dr. Glenn Chertow will present a win-ratio analysis of the cardiovascular safety of Vadadustat in patients with CKD-related anemia undergoing dialysis on June 6 at 8:15 am CEST [2] - An e-poster will discuss the combination of Vadadustat with Ferric Citrate, highlighting its protective effects against inflammation-induced anemia and anemia caused by chronic kidney disease [2] - Insights from a Japanese database study on the real-world use of HIF-PH inhibitors and erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent CKD with anemia will also be presented [2]